CJC-1295 and Ipamorelin are two peptides that are often used together to support the body’s own growth hormone release. People research this pair for muscle, recovery, sleep, and body composition goals. This guide explains what each peptide is, how they work together, what the research actually shows, dosage basics, safety, and the current legal status.
What Is CJC-1295?
CJC-1295 is a man-made peptide based on a natural hormone called growth hormone releasing hormone, or GHRH. GHRH is the signal your brain sends to the pituitary gland to release growth hormone. CJC-1295 copies the active part of this hormone but is built to last much longer in the body. Source: PubMed
In a human study, CJC-1295 raised growth hormone levels by 2 to 10 times for 6 days or more after a single dose, and raised IGF-1 (a hormone the liver makes in response to growth hormone) by 1.5 to 3 times for 9 to 11 days. With repeated doses, IGF-1 stayed above normal levels for up to 28 days. The study also reported an estimated half-life of 5.8 to 8.1 days, and no serious side effects. Source: PubMed
There are two versions sold under the CJC-1295 name, and mixing them up is a common source of confusion:
| Version | Also called | How long it lasts | Typical use pattern |
|---|---|---|---|
| CJC-1295 with DAC | CJC-1295 | Several days (long acting) | Dosed less often, such as weekly |
| CJC-1295 without DAC | Mod GRF (1-29) | About 30 minutes to 2 hours (short acting) | Dosed more often, such as daily |
DAC stands for drug affinity complex. It is the part that binds to a protein in the blood and slows down how fast the body clears the peptide, which is why it lasts so much longer.
What Is Ipamorelin?
Ipamorelin belongs to a different peptide family. It is a growth hormone secretagogue, which means it triggers growth hormone release, but it works through the ghrelin receptor instead of the GHRH receptor. Ghrelin is the hormone best known for triggering hunger, and Ipamorelin mimics part of its signaling to the pituitary gland. Source: Springer Pharmaceutical Research
The original 1998 research on Ipamorelin found that it released growth hormone about as well as older secretagogues, but it did not raise ACTH or cortisol the way GHRP-6 and GHRP-2 did, even at doses more than 200 times higher than what was needed to trigger growth hormone release. This is why it is often called the first “selective” growth hormone secretagogue. Source: European Journal of Endocrinology
A human pharmacokinetic study found Ipamorelin has a short half-life of about 2 hours, meaning it clears from the body quickly. Source: Springer Pharmaceutical Research
How Do CJC-1295 and Ipamorelin Work Together?
The two peptides are often paired because they act on two different doors into the same room.
- CJC-1295 knocks on the GHRH receptor, telling the pituitary gland to prepare to release growth hormone.
- Ipamorelin knocks on the ghrelin receptor, giving a separate signal that triggers the actual release.
Using both at once is meant to produce a stronger combined signal than either peptide alone. This idea makes sense based on how each peptide works on its own, but there is no large, dedicated human trial that measured the CJC-1295 plus Ipamorelin combination directly. Most of what is known comes from studying each peptide separately, so claims about an exact multiplier effect from stacking them should be treated as theory, not a proven number.
Potential Benefits
Because there is limited direct research on the combination itself, each benefit below is explained along with how strong (or weak) the evidence actually is. A summary table follows at the end of this section.
1. Higher growth hormone and IGF-1 levels
This is the most directly supported benefit. In the human CJC-1295 study, growth hormone rose 2 to 10 times and IGF-1 rose 1.5 to 3 times after dosing. Source: PubMed This is measured data from CJC-1295 alone, not the combination with Ipamorelin, but it is the strongest evidence on this list.
2. Better sleep quality
Growth hormone is naturally released in bursts during deep sleep, so it is reasonable to think raising growth hormone could support sleep. However, this specific combination has not been directly tested for sleep outcomes in a controlled study, so this benefit is currently theoretical and based on user reports rather than proof.
3. Improved recovery after exercise
IGF-1 plays a known role in tissue repair, which is why recovery is often mentioned alongside this stack. The link is indirect, though: it comes from what IGF-1 does in general, not from a study that tested CJC-1295 and Ipamorelin for recovery specifically.
4. Changes in body composition (more muscle, less fat)
This is where the evidence is most mixed. Clear improvements in muscle and fat are best documented in people who have a real, diagnosed growth hormone deficiency. In healthy adults with normal growth hormone levels, the effect on body composition is far less established.
Example: if someone already makes normal amounts of growth hormone, the change they may notice is likely smaller than someone whose levels are genuinely low. Most solid data on growth hormone therapy comes from deficient populations, not healthy people looking for a boost.
5. Better mental clarity
This benefit is the weakest on the list. There is no strong human evidence connecting this peptide combination to improved mental clarity in healthy adults, so it should be treated as anecdotal until better research exists.
Summary of the evidence
| Potential benefit | What supports it | Evidence level |
|---|---|---|
| Higher growth hormone and IGF-1 levels | Directly measured in the CJC-1295 human study | Human study (CJC-1295 alone) |
| Better sleep quality | Growth hormone is linked to deep sleep, but this specific combination has not been directly tested for sleep outcomes | Theoretical / user reports |
| Improved recovery after exercise | Related to IGF-1’s known role in tissue repair | Theoretical / indirect |
| Changes in body composition (more muscle, less fat) | Best documented in people with real growth hormone deficiency, not clearly shown in healthy adults | Mixed / limited |
| Better mental clarity | Not supported by strong human evidence for healthy adults | Weak / anecdotal |
Dosage and How It Is Used
There is no FDA approved human dose for either peptide, since neither is an approved medicine. Doses discussed online come from clinics, compounding pharmacies, and research protocols rather than large controlled trials.
General points people research:
- Administration: both are typically given as a subcutaneous injection, meaning just under the skin, often in the stomach area
- Timing: many protocols suggest dosing in the evening, and on a fairly empty stomach, since food and blood sugar changes can affect natural growth hormone release
- Frequency: CJC-1295 with DAC is generally used less often (for example, weekly) because it lasts longer, while CJC-1295 without DAC and Ipamorelin are generally used more often (for example, daily) because they clear the body faster
Because dosing is not standardized, it should only be decided with a licensed provider who can weigh your health history, and it should never be based on a chart found online.
Side Effects and Safety
The original CJC-1295 study reported no serious adverse reactions and described the peptide as generally well tolerated at the doses tested. Source: PubMed That said, this was one study, and long term human safety data for the CJC-1295 plus Ipamorelin combination is still limited.
Effects commonly discussed for this type of peptide include:
- Redness, swelling, or irritation at the injection site
- Headache or flushing
- Water retention or mild swelling
- Joint or muscle discomfort
- Changes in blood sugar, since growth hormone can affect insulin sensitivity
Warning signs that need prompt medical attention include severe headaches, vision changes, chest pain, or fainting.
Who should be extra cautious
Because growth hormone and IGF-1 can influence cell growth, providers generally advise caution or avoidance for people with:
- A personal or strong family history of cancer
- Uncontrolled diabetes
- Untreated sleep apnea
- Pregnancy or breastfeeding, or those trying to conceive
- Significant heart disease
This is general information, not a full list, and it does not replace an individual medical evaluation.
Is CJC-1295 or Ipamorelin FDA Approved or Legal?
Neither CJC-1295 nor Ipamorelin is approved by the FDA as a medicine for any condition. Their status on the FDA’s compounding lists is also different from each other, based on the FDA’s own published list:
- Ipamorelin acetate is currently listed by the FDA as a Category 2 bulk substance, a category for substances the FDA says may pose significant safety risks for compounding. It was added to this list on September 29, 2023, for use in outsourcing facility (503B) compounding. Source: FDA
- CJC-1295 was nominated for one of the FDA’s bulk substance lists, but that nomination was later withdrawn. It does not currently appear on the Category 2 list, but this is not the same as FDA approval. It simply means it is not on that specific restricted list. Source: FDA
These FDA lists are reviewed and updated over time, and rules also vary by country and state. Always confirm the current status with a licensed provider or pharmacy rather than relying on outdated information found online, including this article.
Questions to Ask Your Provider
If you are considering this combination, bring these questions to a licensed provider:
- Is this a reasonable option given my current health and goals?
- What dose and schedule would you recommend, and why?
- What lab tests should be checked before and during use, such as IGF-1 or a metabolic panel?
- What are the warning signs that mean I should stop and call you?
- Where does the product come from, and how is its quality verified?
Frequently Asked Questions
What does CJC-1295 do? It is a modified growth hormone releasing hormone that signals the pituitary gland to release more growth hormone, which then raises IGF-1 in the body. Source: PubMed
What does Ipamorelin do? It triggers growth hormone release through the ghrelin receptor and, in animal research, did so without meaningfully raising cortisol or prolactin. Source: musclescience.org summary of Raun et al.
Is CJC-1295 with Ipamorelin safe? Neither peptide has completed large, long term human safety trials, and the combination itself has not been directly studied. The single CJC-1295 human study reported no serious side effects, but this should still only be used with medical supervision. Source: PubMed
How much CJC-1295 or Ipamorelin should I take? There is no FDA approved or clinically standardized human dose for either peptide. Any decision should be made with a licensed provider.
How long does it take to see results? There is no reliable clinical timeframe for the combination. Reported timelines online come from personal or clinic experience, not controlled studies.
Does CJC-1295 and Ipamorelin increase testosterone? No. Both peptides work on the growth hormone and IGF-1 pathway. They are not designed to directly raise testosterone.
Can Ipamorelin be used with Sermorelin instead of CJC-1295? Sermorelin is another GHRH based peptide, similar in category to CJC-1295 but shorter acting. People sometimes research Ipamorelin alongside either one, but this is a provider level decision.
Is Ipamorelin FDA approved? No. Ipamorelin acetate is currently listed by the FDA as a Category 2 bulk substance, meaning the FDA has flagged it as a possible significant safety risk for compounding. Being on this list is not the same as being banned, and coming off this list would not mean approval either. Source: FDA
Important Health Note
This article is for general information and educational purposes only. It is not medical advice, and it is not a recommendation to buy or use CJC-1295, Ipamorelin, or any peptide. Neither peptide is approved by the FDA to prevent, treat, or cure any disease. Much of the specific research referenced here comes from a single human study on CJC-1295 alone, animal research on Ipamorelin, and general growth hormone science, so results may vary and may not apply to everyone. Always speak with a qualified healthcare professional before starting any peptide, especially if you are pregnant, nursing, managing a health condition, or taking other medications.
Sources
- Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295, Journal of Clinical Endocrinology and Metabolism / PubMed: https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pharmacokinetic-pharmacodynamic modeling of Ipamorelin in human volunteers, Pharmaceutical Research / Springer: https://link.springer.com/article/10.1023/A:1018955126402
- Raun et al., Ipamorelin, the first selective growth hormone secretagogue, European Journal of Endocrinology: https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390
- FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 list): https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks